A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech

Status and phase

Completed

Phase 1

Conditions

Solid Cancers

Treatments

Drug: MNRP1685A

Study type

Interventional

Funder types

Industry

Identifiers

NCT00747734

ANP4509g

Details and patient eligibility

About

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

Enrollment

35 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen
Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measurable disease)

Exclusion criteria

Inadequate hematologic or organ function
Anti-cancer therapy within 4 weeks prior to initiation of study treatment
Recent history of or current clinically significant gastrointestinal, cardiovascular or pulmonary disorders
Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytics, or a filter of the inferior vena cava
Active infection or autoimmune disease
Known human immunodeficiency virus (HIV) infection
Pregnancy or breast feeding